MA32257B1 - Hydroxymethyl pyrrolidines comme agonistes des recepteurs beta-3- adrenergiques. - Google Patents

Hydroxymethyl pyrrolidines comme agonistes des recepteurs beta-3- adrenergiques.

Info

Publication number
MA32257B1
MA32257B1 MA33292A MA33292A MA32257B1 MA 32257 B1 MA32257 B1 MA 32257B1 MA 33292 A MA33292 A MA 33292A MA 33292 A MA33292 A MA 33292A MA 32257 B1 MA32257 B1 MA 32257B1
Authority
MA
Morocco
Prior art keywords
agonists
beta
adrenergic receptors
pyrrolidines
hydroxymethyl
Prior art date
Application number
MA33292A
Other languages
Arabic (ar)
English (en)
Inventor
Richard Berger
Lehua Chang
Scott D Edmondson
Stephen D Goble
Sookhee Nicole Ha
Nam Fung Kar
Ihor E Kopka
Bing Li
Gregori J Morriello
Chris R Moyes
Dong-Ming Shen
Liping Wang
Cheng Zhu
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA32257B1 publication Critical patent/MA32257B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

La présente invention concerne des composés de formule (ia), des compositions pharmaceutiques les comprenant, et des procédés d'utilisation de ceux-ci dans le traitement ou la prévention de maladies médiées par l'activation des adrénorécepteurs ß3.
MA33292A 2008-04-04 2010-10-29 Hydroxymethyl pyrrolidines comme agonistes des recepteurs beta-3- adrenergiques. MA32257B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12306308P 2008-04-04 2008-04-04
US20604309P 2009-01-27 2009-01-27
PCT/US2009/039249 WO2009124166A1 (fr) 2008-04-04 2009-04-02 Hydroxyméthyl pyrrolidines en tant qu’agonistes des récepteurs adrénergiques bêta 3

Publications (1)

Publication Number Publication Date
MA32257B1 true MA32257B1 (fr) 2011-04-01

Family

ID=40671093

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33292A MA32257B1 (fr) 2008-04-04 2010-10-29 Hydroxymethyl pyrrolidines comme agonistes des recepteurs beta-3- adrenergiques.

Country Status (41)

Country Link
US (3) US8399480B2 (fr)
EP (1) EP2276756B9 (fr)
JP (3) JP4783867B2 (fr)
KR (3) KR101331771B1 (fr)
CN (2) CN102056917B (fr)
AR (1) AR072043A1 (fr)
AT (1) ATE535521T1 (fr)
AU (1) AU2009231714B2 (fr)
BR (1) BRPI0909768B1 (fr)
CA (1) CA2719876C (fr)
CL (1) CL2009000815A1 (fr)
CO (1) CO6331440A2 (fr)
CR (2) CR11751A (fr)
CY (1) CY1112552T1 (fr)
DO (2) DOP2010000294A (fr)
EA (1) EA020135B1 (fr)
EC (1) ECSP10010518A (fr)
ES (1) ES2376278T3 (fr)
FI (1) FIC20240046I1 (fr)
FR (1) FR24C1051I2 (fr)
GE (1) GEP20125666B (fr)
HN (1) HN2010002030A (fr)
HR (1) HRP20120129T2 (fr)
IL (1) IL208215A (fr)
MA (1) MA32257B1 (fr)
ME (1) ME01988B (fr)
MX (1) MX2010010929A (fr)
NI (1) NI201000164A (fr)
NL (1) NL301305I2 (fr)
NO (1) NO2024055I1 (fr)
NZ (1) NZ588266A (fr)
PE (1) PE20091825A1 (fr)
PL (1) PL2276756T3 (fr)
PT (1) PT2276756E (fr)
RS (1) RS52175B (fr)
SG (1) SG188883A1 (fr)
SI (1) SI2276756T1 (fr)
SV (1) SV2010003687A (fr)
TW (1) TWI378098B (fr)
WO (2) WO2009124166A1 (fr)
ZA (1) ZA201006720B (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4891872A (en) 1988-05-09 1990-01-09 Sussman Martin V Apparatus for incrementally drawing fibers
PE20091825A1 (es) * 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
MX2012002366A (es) * 2009-08-27 2012-03-29 Merck Sharp & Dohme Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina.
WO2011043942A1 (fr) * 2009-10-07 2011-04-14 Merck Sharp & Dohme Corp. Polythérapie utilisant un agoniste des récepteurs adrénergiques bêta-3 et un agent antimuscarinique
WO2011137054A1 (fr) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Nouveaux agonistes du récepteur bêta 3 adrénergique
CN103140134B (zh) * 2010-07-23 2015-07-29 默沙东公司 新吡咯烷衍生的β3肾上腺素能受体激动剂
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
AU2011285928B9 (en) * 2010-08-03 2018-08-02 B3Ar Therapeutics, Inc. Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
GB2484713A (en) 2010-10-21 2012-04-25 Optovate Ltd Illumination apparatus
EP2742030B1 (fr) * 2011-08-11 2016-07-27 Bayer Intellectual Property GmbH Cetoenols 1,2,4-triazolyl-substitues destines a la protection des plantes
WO2013062881A1 (fr) * 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Procédé de préparation d'agonistes bêta 3 et d'intermédiaires associés
ES2584427T3 (es) 2011-10-27 2016-09-27 Merck Sharp & Dohme Corp. Proceso para la preparación de agonistas beta 3 y productos intermedios
IN2014CN04470A (fr) 2011-11-18 2015-09-04 Codexis Inc
TW201338772A (zh) 2012-02-09 2013-10-01 Altherx Inc 藥學組合物
JP2015178458A (ja) * 2012-07-25 2015-10-08 杏林製薬株式会社 ベンゼン環縮合含窒素５員複素環式化合物、またはその薬理学的に許容される塩
US9784726B2 (en) 2013-01-08 2017-10-10 Atrogi Ab Screening method, a kit, a method of treatment and a compound for use in a method of treatment
EP2968323A4 (fr) 2013-03-13 2016-12-14 Flatley Discovery Lab Composés de pyridazinone et procédés pour le traitement de fibrose kystique
RS59402B1 (sr) * 2013-03-15 2019-11-29 Merck Sharp & Dohme Postupak za pripremu beta 3 agonista i međuproizvoda
CN103232352B (zh) * 2013-05-11 2015-12-23 苏州永健生物医药有限公司 (r)-4-(2-(2-羟基-2-苯乙胺基)乙基)苯胺基甲酸叔丁基酯
CN103760286A (zh) * 2014-01-14 2014-04-30 北京万全德众医药生物技术有限公司 一种用高效液相色谱法测定琥珀酸索非那新中间体光学纯度的方法
PT3154989T (pt) 2014-06-11 2021-05-18 Venatorx Pharmaceuticals Inc Inibidores de beta-lactamase
HK1245117A1 (zh) 2014-12-03 2018-08-24 Velicept Therapeutics, Inc. 使用调节释放索拉贝隆用於下尿路症状的组合物和方法
KR20170103962A (ko) * 2015-01-20 2017-09-13 머크 샤프 앤드 돔 코포레이션 인자 xia 억제제
ES2967863T3 (es) 2015-10-23 2024-05-06 B3Ar Therapeutics Inc Ion dipolar de solabegron y usos del mismo
EP3463307A4 (fr) * 2016-06-03 2020-01-15 Velicept Therapeutics, Inc. Compositions et méthodes d'utilisation du solabégron à libération modifiée pour traiter des symptômes du bas appareil urinaire
GB201705365D0 (en) 2017-04-03 2017-05-17 Optovate Ltd Illumination apparatus
GB201705364D0 (en) 2017-04-03 2017-05-17 Optovate Ltd Illumination apparatus
EP3630783A4 (fr) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. Inhibiteurs protéiques de liaison à la pénicilline
JP7670461B2 (ja) 2017-06-06 2025-04-30 ウロバント サイエンシズ ゲゼルシャフト ミット ベシュレンクター ハフトゥング 過活動膀胱の治療のためのビベグロンの投薬
EP3634420A1 (fr) 2017-06-06 2020-04-15 Urovant Sciences GmbH Utilisation de vibegron dans le traitement de la vessie hyperactive
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201718307D0 (en) 2017-11-05 2017-12-20 Optovate Ltd Display apparatus
KR102735800B1 (ko) * 2017-12-21 2024-11-28 교린 세이야쿠 가부시키가이샤 야간빈뇨 치료제
GB201800574D0 (en) 2018-01-14 2018-02-28 Optovate Ltd Illumination apparatus
GB201803767D0 (en) 2018-03-09 2018-04-25 Optovate Ltd Illumination apparatus
GB201807747D0 (en) 2018-05-13 2018-06-27 Optovate Ltd Colour micro-LED display apparatus
SG11202010683PA (en) 2018-05-23 2020-12-30 Urovant Sciences Gmbh Use of vibegron to treat pain associated with irritable bowel syndrome
EP3802551A4 (fr) 2018-05-25 2022-03-02 Venatorx Pharmaceuticals, Inc. Inhibiteurs de protéine de liaison à la pénicilline
SG11202103662VA (en) * 2018-12-05 2021-06-29 Urovant Sciences Gmbh Vibegron for the treatment of overactive bladder symptoms
CN109503500A (zh) * 2018-12-17 2019-03-22 天津药明康德新药开发有限公司 一种2-(2-氧代吡嗪-1(2h)-基)乙酸的合成方法
CN109734712B (zh) * 2019-01-30 2020-10-20 广东东阳光药业有限公司 芳基或杂芳基取代的吡咯烷酰胺衍生物及其用途
JP2022524576A (ja) 2019-03-18 2022-05-09 ウロバント サイエンシズ ゲーエムベーハー 過活動膀胱を処置するためのビベグロンの使用
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
TWI912252B (zh) 2019-07-02 2026-01-21 美商瑞爾Ｄ斯帕克有限責任公司 定向顯示設備
JP7685306B2 (ja) 2019-08-23 2025-05-29 リアルディー スパーク エルエルシー 指向性照明装置およびプライバシーディスプレイ
WO2021050967A1 (fr) 2019-09-11 2021-03-18 Reald Spark, Llc Appareil d'éclairage directionnel et affichage de confidentialité
US11163101B2 (en) 2019-09-11 2021-11-02 Reald Spark, Llc Switchable illumination apparatus and privacy display
US11162661B2 (en) 2019-10-03 2021-11-02 Reald Spark, Llc Illumination apparatus comprising passive optical nanostructures
EP4038313A4 (fr) 2019-10-03 2023-11-22 RealD Spark, LLC Appareil d'éclairage comprenant des nanostructures optiques passives
CN115136065A (zh) 2020-02-20 2022-09-30 瑞尔D斯帕克有限责任公司 照明和显示设备
JP2023534704A (ja) * 2020-07-22 2023-08-10 ヤンセン ファーマシューティカ エヌ．ベー． 第ｘｉａ因子阻害剤として有用な化合物
CA3202926A1 (fr) 2020-12-22 2022-06-30 Paul N. Mudd Jr. Procedes de surveillance de la digoxine avec utilisation concomitante de vibegron pour le traitement d'une vessie hyperactive
TW202245781A (zh) 2021-02-16 2022-12-01 瑞士商優洛凡特科學公司 用維貝格龍（ｖｉｂｅｇｒｏｎ）治療心臟衰竭之方法
WO2022271582A1 (fr) 2021-06-22 2022-12-29 Reald Spark, Llc Appareil d'éclairage
GB202113588D0 (en) 2021-09-23 2021-11-10 Atrogi Ab New compounds and methods
WO2023168365A1 (fr) 2022-03-02 2023-09-07 Jds Therapeutics, Llc Compositions d'acide polyglutamique et procédés d'utilisation
GB202205895D0 (en) 2022-04-22 2022-06-08 Atrogi Ab New medical uses
CN114920771A (zh) * 2022-05-13 2022-08-19 苏州虞美景盛新药开发有限公司 一种用于膀胱过度活动症的口服新药的中间体新合成工艺
CN120187454A (zh) * 2022-10-18 2025-06-20 博纳菲德健康有限公司 β-肾上腺素能激动剂和毒蕈碱性拮抗剂组合物及使用方法
CN115850286B (zh) * 2022-12-05 2023-08-22 奥锐特药业(天津)有限公司 一种维贝格龙中间体及其制备方法
CN117756809A (zh) * 2023-12-21 2024-03-26 苏州莱克施德药业有限公司 (6s)4,6,7,8-四氢-4-氧代吡咯并[1,2-a]嘧啶-6-羧酸甲酯的合成方法
WO2025262600A1 (fr) 2024-06-17 2025-12-26 Urovant Sciences Gmbh Forme cristalline d'hémihydrate de vibégron

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
DOP2003000587A (es) 2002-02-27 2003-08-30 Pfizer Prod Inc AGONISTAS DEL RECEPTOR ß3-ADRENERGICO
DK1559427T3 (da) * 2002-11-07 2011-04-26 Astellas Pharma Inc Lægemiddel til overaktiv blære omfattende eddikesyreanilidderivat som den aktive bestanddel
FR2874011B1 (fr) * 2004-08-03 2007-06-15 Sanofi Synthelabo Derives de sulfonamides, leur preparation et leur application en therapeutique
PE20091825A1 (es) * 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3

Also Published As

Publication number Publication date
RS52175B (sr) 2012-08-31
SI2276756T1 (sl) 2012-04-30
EP2276756B9 (fr) 2012-08-15
CL2009000815A1 (es) 2009-08-21
CA2719876C (fr) 2013-10-01
JP2011510023A (ja) 2011-03-31
KR101288798B1 (ko) 2013-07-23
EP2276756B1 (fr) 2011-11-30
KR20120104257A (ko) 2012-09-20
NI201000164A (es) 2011-06-21
ZA201006720B (en) 2011-05-25
WO2009124167A1 (fr) 2009-10-08
KR20100126860A (ko) 2010-12-02
HK1147099A1 (en) 2011-07-29
US8247415B2 (en) 2012-08-21
KR20120118086A (ko) 2012-10-25
CN102056917A (zh) 2011-05-11
IL208215A (en) 2014-04-30
KR101331771B1 (ko) 2013-11-22
JP4783870B1 (ja) 2011-09-28
WO2009124166A1 (fr) 2009-10-08
JP5432846B2 (ja) 2014-03-05
EP2276756B8 (fr) 2012-04-11
GEP20125666B (en) 2012-10-10
BRPI0909768B1 (pt) 2019-01-15
CN102056917B (zh) 2014-11-05
TWI378098B (en) 2012-12-01
CY1112552T1 (el) 2016-02-10
HRP20120129T1 (hr) 2012-03-31
DOP2013000267A (es) 2014-01-31
NZ588266A (en) 2011-11-25
IL208215A0 (en) 2010-12-30
CA2719876A1 (fr) 2009-10-08
CO6331440A2 (es) 2011-10-20
DOP2010000294A (es) 2010-12-31
EA201071169A1 (ru) 2011-04-29
NO2024055I1 (no) 2024-12-12
CR20120282A (es) 2012-07-03
ATE535521T1 (de) 2011-12-15
MX2010010929A (es) 2010-11-12
CN102391255A (zh) 2012-03-28
US8399480B2 (en) 2013-03-19
CR11751A (es) 2010-11-22
TW200944521A (en) 2009-11-01
HRP20120129T8 (en) 2012-04-30
ME01988B (fr) 2012-08-31
JP4783867B2 (ja) 2011-09-28
FR24C1051I2 (fr) 2026-01-16
PE20091825A1 (es) 2009-12-04
HN2010002030A (es) 2012-08-13
ECSP10010518A (es) 2010-11-30
JP2011201897A (ja) 2011-10-13
EA020135B1 (ru) 2014-08-29
PT2276756E (pt) 2012-02-03
NL301305I2 (nl) 2024-12-30
ES2376278T3 (es) 2012-03-12
FR24C1051I1 (fr) 2025-01-17
SV2010003687A (es) 2011-03-23
AU2009231714B2 (en) 2011-11-03
BRPI0909768A2 (pt) 2015-10-06
JP2012020961A (ja) 2012-02-02
HRP20120129T2 (hr) 2012-09-30
US20120258963A1 (en) 2012-10-11
US20110028481A1 (en) 2011-02-03
SG188883A1 (en) 2013-04-30
EP2276756A1 (fr) 2011-01-26
US20090253705A1 (en) 2009-10-08
CN102391255B (zh) 2014-07-09
AR072043A1 (es) 2010-08-04
PL2276756T3 (pl) 2012-04-30
US8653260B2 (en) 2014-02-18
AU2009231714A1 (en) 2009-10-08
FIC20240046I1 (fi) 2024-12-16

Similar Documents

Publication Publication Date Title
MA32257B1 (fr) Hydroxymethyl pyrrolidines comme agonistes des recepteurs beta-3- adrenergiques.
MA32226B1 (fr) Compositions et leurs procedes de preparation et d'utilisation
MA32729B1 (fr) Derives d'acide 1-amino-2-cyclobutylethylboronique
MA30914B1 (fr) Dihydropyrazolones substituees utilisees dans le traitement de maladies cardiovasculaires et hematologiques.
MA34169B1 (fr) Dérivés d'acide 1-amino-2-cyclopropyléthylboronique
MA34765B1 (fr) Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
MA31952B1 (fr) Pyrrolopyrimidines et pyrrolopyridines
MA37891B1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
WO2019035863A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques
MA32471B1 (fr) Composés de borates esters et compositions pharmaceutiques contenant des composés
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
MA30207B1 (fr) Modulateurs des recepteurs de la progesterone a base d'indole sulfonamide
EA200800564A1 (ru) Производные ксантина как селективные агонисты нм74а
EP2614860A4 (fr) Composition pharmaceutique pour le traitement de l'oeil sec
MA31683B1 (fr) Composes et procedes pour moduler fxr
JO2686B1 (en) Vehicles
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
BRPI0721137B8 (pt) compostos para modulação de atividade de c-fms e/ou kit, composição, kit e uso dos referidos compostos.
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
TW200608960A (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
MA47356A1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
MA33679B1 (fr) Derives de 2-oxo-1-pyrrolidinyle imidazothiadiazole
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)